一例IgG4相关性疾病报道

2013-07-19 王玉玲 孟自力 医学论坛网

  近日,江苏省淮安市一院呼吸科孟自力主任医师成功诊断一例“IgG4相关性疾病”。“IgG4相关性疾病”是一种淋巴增殖性疾病,表现为高IgG4球蛋白血症,及IgG4+ 淋巴浆细胞浸润单个或多个器官,合并受累器官的纤维化、硬化及功能异常,最常受累的器官(疾病)包括自身免疫性胰腺炎、硬化性胆管炎、硬化性涎腺炎、腹膜后纤维化、以及肝、肺、肾、垂体、甲状腺受累等。该病2010年才在世界上

  近日,江苏省淮安市一院呼吸科孟自力主任医师成功诊断一例“IgG4相关性疾病”。“IgG4相关性疾病”是一种淋巴增殖性疾病,表现为高IgG4球蛋白血症,及IgG4+ 淋巴浆细胞浸润单个或多个器官,合并受累器官的纤维化、硬化及功能异常,最常受累的器官(疾病)包括自身免疫性胰腺炎、硬化性胆管炎、硬化性涎腺炎、腹膜后纤维化、以及肝、肺、肾、垂体、甲状腺受累等。该病2010年才在世界上获得确认,2011年公布的最新诊断标准为:⑴ 临床发现单个或多个器官出现弥漫性或局限性肿胀、团块;⑵ 血清IgG4浓度大于1350mg/L;⑶ 组织病理学检测显示明显的淋巴浆细胞浸润及纤维化,IgG4+ 浆细胞大于10个/HP,IgG4+/ IgG+浆细胞大于40%。

  该患者为男性,56岁,油漆工人,因“反复咳嗽、咳痰、气喘伴双上眼睑肿胀1年”就诊,体检两肺弥漫性呼气期为主的哮鸣音,肺功能检查示中度阻塞性通气功能障碍,支气管舒张试验阳性,因此,“支气管哮喘”诊断成立。体检时还发现患者双上眼睑明显肿胀,触之质地中等硬度,B超及头颅CT均发现患者双侧泪腺、腮腺和颌下腺肿大,随后在局麻下行左侧泪腺活检术,病理报告:慢性硬化性涎腺炎。孟自力主任考虑到患者经济困难,遂自己出资将患者的病理标本送到南京军区总院病理科做免疫组化检测,结果报告:IgG++,IgG4++。为了检测患者血清中的IgG4浓度,孟自力主任打听了省内各大医院的检验科和医学检测中心,可是均不开展该项目的检查,就在一筹莫展的时候,无意中得知淮安一院的免疫室刚刚开展该项检查,于是患者的血样幸运地成为该项新技术的第一份检测标本,为了验证检查的准确性,孟自力主任又亲自抽取自身血液作为对照,检测结果:IgG16.20(8.00~17.00g/L),IgG4 14.90(0.03~2.00 g/L),至此,“IgG4相关性疾病”诊断确立。该病对糖皮质激素非常敏感,经强的松(30mg/d)治疗1月后,患者咳喘基本消失,双上眼睑肿胀也明显好转,目前仍在随访中。    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837122, encodeId=6338183e1228f, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Nov 12 11:15:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350147, encodeId=dc13135014ed6, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482959, encodeId=0b65148295981, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615171, encodeId=b5cb16151e1a6, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837122, encodeId=6338183e1228f, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Nov 12 11:15:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350147, encodeId=dc13135014ed6, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482959, encodeId=0b65148295981, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615171, encodeId=b5cb16151e1a6, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837122, encodeId=6338183e1228f, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Nov 12 11:15:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350147, encodeId=dc13135014ed6, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482959, encodeId=0b65148295981, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615171, encodeId=b5cb16151e1a6, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837122, encodeId=6338183e1228f, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Nov 12 11:15:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350147, encodeId=dc13135014ed6, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482959, encodeId=0b65148295981, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615171, encodeId=b5cb16151e1a6, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sun Jul 21 14:15:00 CST 2013, time=2013-07-21, status=1, ipAttribution=)]